Cabozantinib for Metastatic Triple Negative BrCa

Inclusion Criteria:

Histologically or cytologically confirmed invasive breast cancer with stage IV disease
Primary tumor and/or metastasis must be ER-negative, PR-negative and HER2-negative
May have received 0-3 prior chemotherapeutic regimens for metastatic breast cancer. Must be off treatment for at least 21 days prior to enrollment
Must have discontinued all biologic therapy at least 14 days before enrollment
May have received prior radiation therapy in the early stage or metastatic setting, but must have completed treatment at least 14 days prior to enrollment
Must agree to use medically acceptable methods of contraception
Confirmed availability of formalin-fixed, paraffin-embedded tumor tissue
Able to swallow tablets

Exclusion Criteria:

Pregnant or breastfeeding
Received another investigational agent within 14 days prior to enrollment
Received prior c-Met inhibitor
Known brain metastases that are untreated, symptomatic or require therapy to control symptoms
Psychiatric illness or social situation that could limit ability to comply with study requirements
Require concomitant treatment in therapeutic doses with anticoagulants or antiplatelet agents
Diagnosis of another malignancy requiring systemic treatment within the last two years (except non-melanoma skin cancer or in-situ carcinoma of the cervix)
Known to be positive for HIV
Active infection requiring IV antibiotics at Day 1 of cycle 1
Uncontrolled, significant intercurrent illness
Requires chronic concomitant treatment of a strong CYP3A4 inducer
tumor in contact with, invading or encasing major blood vessels
Have experienced clinically significant gastrointestinal bleeding within 6 months, hemoptysis of more than 0.5 teaspoon of red blood within 3 months or other signs indicative of pulmonary hemorrhage within 3 months of enrollment